Clincosm LogoSign in Get a demo

respiratory syncytial virus infections

Showing 26 - 50 of 132
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Respiratory Syncytial Virus Infections Trial in New Zealand, Panama, South Africa (RSVPreF3 OA investigational vaccine, FLU-QIV)

Completed
Has Results
  • Respiratory Syncytial Virus Infections
  • RSVPreF3 OA investigational vaccine
  • FLU-QIV
  • Auckland, New Zealand
  • +13 more
Sep 20, 2022

Respiratory Syncytial Virus Infections Trial in Worldwide (MEDI8897, Palivizumab)

Active, not recruiting
  • Respiratory Syncytial Virus Infections
  • Anaheim, California
  • +127 more
Aug 18, 2022

Influenza, Human, Respiratory Syncytial Virus Infections Trial in United States (Swab)

Recruiting
  • Influenza, Human
  • Respiratory Syncytial Virus Infections
  • Swab
  • Birmingham, Alabama
  • +19 more
Aug 16, 2022

Respiratory Syncytial Virus Infections Trial in Canada, Sweden, United States (RSVPreF3 OA investigational vaccine)

Completed
  • Respiratory Syncytial Virus Infections
  • RSVPreF3 OA investigational vaccine
  • Waterbury, Connecticut
  • +19 more
Aug 5, 2022

Respiratory Syncytial Virus Infections Trial in Worldwide (RSVPreF3 OA investigational vaccine)

Active, not recruiting
  • Respiratory Syncytial Virus Infections
  • RSVPreF3 OA investigational vaccine
  • Mobile, Alabama
  • +45 more
Jul 22, 2022

Respiratory Syncytial Virus Infections Trial in Worldwide (RSV MAT Lot 1 vaccine (GSK3888550A), RSV MAT Lot 2 vaccine

Completed
  • Respiratory Syncytial Virus Infections
  • RSV MAT Lot 1 vaccine (GSK3888550A)
  • +4 more
  • West Palm Beach, Florida
  • +35 more
Jul 14, 2022

Respiratory Syncytial Virus Infections Trial in Belgium, United States (RSVPreF3 OA investigational vaccine (GSK3844766A))

Completed
Has Results
  • Respiratory Syncytial Virus Infections
  • RSVPreF3 OA investigational vaccine (GSK3844766A)
  • Lenexa, Kansas
  • +9 more
Jun 2, 2022

Respiratory Syncytial Virus Infections Trial (Nirsevimab)

Not yet recruiting
  • Respiratory Syncytial Virus Infections
  • (no location specified)
Jun 24, 2022

Respiratory Syncytial Virus Infections, Influenza, Human Trial in London (RSV A Memphis 37, Influenza A/California/04/2009)

Terminated
  • Respiratory Syncytial Virus Infections
  • Influenza, Human
  • RSV A Memphis 37
  • Influenza A/California/04/2009
  • London, United Kingdom
    National Heart and Lung Institute, Imperial College London
Jun 23, 2022

Respiratory Syncytial Virus Infections Trial in United States (AZM Group, Control Group)

Recruiting
  • Respiratory Syncytial Virus Infections
  • AZM Group
  • Control Group
  • Birmingham, Alabama
  • +4 more
Jun 16, 2022

Respiratory Syncytial Virus Infections Trial in Worldwide (EDP-938, Placebo)

Recruiting
  • Respiratory Syncytial Virus Infections
  • Augusta, Georgia
  • +59 more
May 27, 2022

Respiratory Syncytial Virus Infections Trial in United States (Saline Placebo (0.5mL injection), RSV F vaccine (0.5mL

Completed
  • Respiratory Syncytial Virus Infections
  • Saline Placebo (0.5mL injection)
  • RSV F vaccine (0.5mL injection)
  • Nampa, Idaho
  • +6 more
May 25, 2022

Respiratory Syncytial Virus Infections Trial in Worldwide (JNJ-53718678, Placebo)

Terminated
  • Respiratory Syncytial Virus Infections
  • Madera, California
  • +168 more
May 11, 2022

Respiratory Syncytial Virus Infections Trial in China (AK0529, Matching of AK0529)

Completed
  • Respiratory Syncytial Virus Infections
  • AK0529
  • Matching placebo of AK0529
  • Beijing, China
  • +27 more
Mar 31, 2022

Respiratory Syncytial Virus Infections Trial in Missoula, Norfolk (RSV MAT)

Withdrawn
  • Respiratory Syncytial Virus Infections
  • RSV MAT
  • Missoula, Montana
  • +1 more
Mar 31, 2022

Respiratory Syncytial Virus Infections Trial in Worldwide (JNJ-53718678 250 mg, Placebo, JNJ-53718678 125 mg)

Terminated
  • Respiratory Syncytial Virus Infections
  • JNJ-53718678 250 mg
  • +2 more
  • Los Angeles, California
  • +68 more
Mar 3, 2022

Respiratory Syncytial Virus Infections Trial in Fukuoka (RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B, Placebo)

Completed
Has Results
  • Respiratory Syncytial Virus Infections
  • RSV_PreF3 Vaccine (GSK3844766A) adjuvanted with AS01B
  • Placebo
  • Fukuoka, Japan
    GSK Investigational Site
Dec 7, 2021

Respiratory Syncytial Virus Infections Trial in Baltimore (rRSV A/Maryland/001/11)

Suspended
  • Respiratory Syncytial Virus Infections
  • rRSV A/Maryland/001/11
  • Baltimore, Maryland
    Johns Hopkins Bloomberg School of Public Health
Feb 8, 2022

Respiratory Syncytial Virus Infections Trial in Worldwide (MEDI8897, Placebo)

Active, not recruiting
  • Respiratory Syncytial Virus Infections
  • Birmingham, Alabama
  • +214 more
Feb 4, 2022

Respiratory Syncytial Virus Infections Trial in United States (D46/NS2/N/?M2-2-HindIII, Placebo)

Completed
Has Results
  • Respiratory Syncytial Virus Infections
  • D46/NS2/N/ΔM2-2-HindIII
  • Placebo
  • Los Angeles, California
  • +9 more
Jan 13, 2022

Respiratory Syncytial Virus Infections Trial in Shinjuku-Ku (VN-0200, Placebo)

Completed
  • Respiratory Syncytial Virus Infections
  • VN-0200
  • Placebo
  • Shinjuku-Ku, Tokyo, Japan
    Medical Corporation Association Shinanokai Shinanozaka Clinic
Dec 21, 2021

Respiratory Syncytial Virus Infections Trial in Worldwide (RSV MAT 60 µg, RSV MAT 120 µg, Placebo)

Completed
Has Results
  • Respiratory Syncytial Virus Infections
  • RSV MAT 60 µg
  • +2 more
  • Phoenix, Arizona
  • +31 more
Nov 12, 2021

Respiratory Syncytial Virus Infections Trial in Belgium, Canada, United States (RSVPreF3 formulation 3, RSVPreF3 formulation 2,

Active, not recruiting
  • Respiratory Syncytial Virus Infections
  • RSVPreF3 formulation 3
  • +4 more
  • Miami, Florida
  • +7 more
Nov 12, 2021

Respiratory Syncytial Virus Infections Trial in United States (RSV LID cp ?M2-2 Vaccine, Placebo)

Terminated
Has Results
  • Respiratory Syncytial Virus Infections
  • RSV LID cp ΔM2-2 Vaccine
  • Placebo
  • Los Angeles, California
  • +4 more
Nov 4, 2021

Respiratory Syncytial Virus Infections Trial in Worldwide (RSV (GSK3389245A) low dose formulation vaccine, RSV (GSK3389245A)

Completed
Has Results
  • Respiratory Syncytial Virus Infections
  • RSV (GSK3389245A) low dose formulation vaccine
  • +3 more
  • Anaheim, California
  • +23 more
Sep 28, 2021